Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study.

Callegari, Ernesto; Tse, Susanna; Doran, Angela C; Goosen, Theunis C; Shaik, Naveed

Callegari, Ernesto; Tse, Susanna; Doran, Angela C; Goosen, Theunis C; Shaik, Naveed.

Afiliação

Callegari E; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Tse S; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Doran AC; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Goosen TC; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA.
Shaik N; Clinical Pharmacology and Bioanalytics, Pfizer Inc., La Jolla, CA, USA.

J Clin Pharmacol ; 64(1): 80-93, 2024 Jan.

Article em En | MEDLINE | ID: mdl-37731282

Assuntos

Indutores do Citocromo P-450 CYP3A; Rifampina; Humanos; Cetoconazol/farmacologia; Citocromo P-450 CYP3A/metabolismo; Proteínas Hedgehog; Inibidores do Citocromo P-450 CYP3A; Interações Medicamentosas; Modelos Biológicos

Palavras-chave

AML; CYP3A4; acute myeloid leukemia; drug-drug interaction; glasdegib; physiologically based pharmacokinetic modeling

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Indutores do Citocromo P-450 CYP3A Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: J Clin Pharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google